A Phase II Study to Determine the Response Kinetics, Safety, and Efficacy of Brentuximab Vedotin and Nivolumab Alone and Then Combined With Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone for Patients With Untreated Primary Mediastinal Large B-Cell Lymphoma
Latest Information Update: 28 Aug 2024
At a glance
- Drugs Brentuximab vedotin (Primary) ; Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Nivolumab (Primary) ; Prednisone (Primary) ; Rituximab (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Acronyms Pacific
- 17 Jun 2022 Preliminary data from this study presented at the 27th Congress of the European Haematology Association
- 07 Jun 2022 Trial design presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 14 Dec 2021 Trial design, presented at the 63rd American Society of Hematology Annual Meeting and Exposition.